Opportunity Information: Apply for PA 12 293
Apply for PA 12 293
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Abuse Aspects of HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 25, 2012 and posted on Sep 25, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses City or township governments Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) County governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Private institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Abuse Aspects of HIV/AIDS (R01) opportunity (Funding Opportunity Number PA 12-293) was a National Institute on Drug Abuse (NIDA) funding announcement under the National Institutes of Health (NIH) that supported investigator-initiated Research Project Grant (R01) studies focused on how drug use and addiction intersect with HIV/AIDS. The central purpose was to encourage research that clarifies and reduces HIV risk and HIV-related harm among people who use drugs, whether through injection or non-injection routes, and among their sexual partners. In practice, this meant the program was looking for well-designed projects that can explain changing patterns of HIV transmission and disease in drug-using populations, and that can translate those insights into stronger prevention and treatment strategies.
A major emphasis of the announcement was on drug-related risk behaviors and the real-world contexts in which risk occurs. Projects were encouraged to identify and predict shifts in the epidemiology of HIV/AIDS among people who inject drugs and those who use drugs without injecting, recognizing that HIV risk can be driven both by direct exposure (such as syringe sharing) and by indirect pathways (such as sexual risk behavior associated with substance use, unstable housing, incarceration, stigma, or limited healthcare access). The FOA also highlighted the need to examine addiction as a chronic condition that can influence HIV acquisition, engagement in care, and health outcomes over time, including how substance use disorders affect adherence to HIV medications, retention in treatment, and viral suppression.
Another key theme was co-morbidities and broader consequences of co-occurring drug use and HIV. The opportunity encouraged research on the medical, psychological, and social complications that can arise when HIV infection occurs in the context of substance use and addiction. This could include studying how drug use contributes to co-infections, mental health conditions, organ system impacts, or other clinical complications, as well as the downstream consequences for quality of life, healthcare utilization, and mortality. Importantly, the FOA also called for basic and mechanistic research that examines HIV infection and AIDS pathogenesis in the presence of drugs of abuse, meaning applicants could propose studies that probe biological mechanisms through which substances may influence immune function, viral replication, inflammation, or disease progression.
Intervention development and testing were strongly encouraged, spanning both primary prevention (preventing new infections) and secondary prevention (reducing transmission and improving outcomes among people living with HIV). The announcement specifically referenced drug treatment interventions as an important lever for improving HIV testing, counseling, linkage to care, and ongoing treatment services. This reflects a broader public health logic: effective substance use treatment and harm reduction can reduce exposure risk, increase contact with healthcare systems, and improve the stability needed for consistent HIV care. Competitive applications under this FOA would typically be expected to present a clear rationale for the intervention approach, a credible study design, meaningful outcomes (behavioral, clinical, or implementation-related), and a plan to reach populations at elevated risk.
From an administrative standpoint, this was a discretionary grant opportunity using the NIH R01 mechanism, and it did not require cost sharing or matching. It was posted on September 25, 2012, with an original and final closing date of January 7, 2016, and it was archived on February 7, 2016. While the opportunity is no longer open, the scope is still representative of NIDA priorities at the time: integrating substance use research with HIV prevention and care, supporting work across epidemiology, behavioral science, clinical research, and basic biology, and emphasizing interventions that can realistically improve outcomes for populations affected by both addiction and HIV.
Eligibility was broad and included many types of U.S. and non-U.S. organizations. Eligible applicants included for-profit entities (including small businesses), nonprofits with or without 501(c)(3) status, public and private institutions of higher education, and various levels of government (state, county, city/township, special district), as well as tribal governments and tribal organizations. The FOA explicitly allowed foreign organizations and foreign institutions to apply, and it also allowed non-U.S. components of U.S. organizations and foreign components as defined in NIH policy. It also clarified that a wide range of mission-focused institutions and community-serving entities could participate, including faith-based and community-based organizations, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and U.S. territories or possessions. The CFDA number associated with this program area was 93.279 (Drug Abuse and Addiction Research Programs).
For further details, the announcement pointed applicants to the NIH grants posting page (http://grants.nih.gov/grants/guide/pa-files/PA-12-293.html) and provided NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues (FBOWebmaster@OD.NIH.GOV).
Frequently Asked Questions (FAQs): Drug Abuse Aspects of HIV/AIDS (R01) - PA-12-293
1) What is the Drug Abuse Aspects of HIV/AIDS (R01) funding opportunity?
This was a National Institute on Drug Abuse (NIDA) funding announcement under the National Institutes of Health (NIH) for investigator-initiated Research Project Grant (R01) studies focused on how drug use and addiction intersect with HIV/AIDS. The funding opportunity number was PA-12-293.
2) What was the central purpose of PA-12-293?
The central purpose was to encourage research that clarifies and reduces HIV risk and HIV-related harm among people who use drugs (through injection or non-injection routes) and among their sexual partners. The program sought projects that could explain changing patterns of HIV transmission and disease in drug-using populations and translate findings into stronger prevention and treatment strategies.
3) What grant mechanism did this opportunity use?
The opportunity used the NIH Research Project Grant (R01) mechanism.
4) Was cost sharing or matching required?
No. The announcement stated that it did not require cost sharing or matching.
5) Is this funding opportunity still open?
No. It is no longer open. It was archived on February 7, 2016.
6) What were the key dates for PA-12-293?
It was posted on September 25, 2012. The original and final closing date was January 7, 2016. It was archived on February 7, 2016.
7) Which NIH institute issued this announcement?
The funding announcement was issued by the National Institute on Drug Abuse (NIDA), which is part of the NIH.
8) What kinds of research topics were encouraged?
The announcement encouraged well-designed projects addressing how drug use and addiction relate to HIV risk, HIV transmission patterns, engagement in HIV care, and HIV health outcomes. It supported research across epidemiology, behavioral science, clinical research, and basic/mechanistic biology, with a strong emphasis on real-world contexts and practical interventions.
9) Did the FOA focus only on injection drug use?
No. It explicitly included both people who inject drugs and people who use drugs without injecting, and it also emphasized risk among their sexual partners.
10) What kinds of HIV risk pathways did the FOA highlight?
It highlighted both direct exposure pathways (for example, syringe sharing) and indirect pathways (for example, sexual risk behavior associated with substance use). It also noted that HIV risk can be shaped by contextual factors such as unstable housing, incarceration, stigma, and limited access to healthcare.
11) How did the FOA frame addiction in relation to HIV?
It emphasized addiction as a chronic condition that can influence HIV acquisition, engagement in care, and health outcomes over time. This included how substance use disorders may affect adherence to HIV medications, retention in treatment, and viral suppression.
12) Did the opportunity include co-morbidities and broader consequences?
Yes. It encouraged research on medical, psychological, and social complications when HIV occurs in the context of substance use and addiction, including downstream effects on quality of life, healthcare utilization, and mortality.
13) What kinds of clinical or health complications were within scope?
Within scope were complications such as co-infections, mental health conditions, organ system impacts, and other clinical complications that may arise or worsen when HIV infection occurs alongside substance use and addiction.
14) Was basic or mechanistic research allowed?
Yes. The FOA called for basic and mechanistic research examining HIV infection and AIDS pathogenesis in the presence of drugs of abuse, including studies of biological mechanisms by which substances may influence immune function, viral replication, inflammation, or disease progression.
15) Were intervention development and testing encouraged?
Yes. Intervention development and testing were strongly encouraged and could include both primary prevention (preventing new HIV infections) and secondary prevention (reducing transmission and improving outcomes among people living with HIV).
16) Did the FOA mention drug treatment interventions specifically?
Yes. It specifically referenced drug treatment interventions as an important lever for improving HIV testing, counseling, linkage to care, and ongoing treatment services.
17) What would competitive intervention applications typically be expected to include?
Based on the description, competitive applications would typically be expected to include a clear rationale for the intervention approach, a credible study design, meaningful outcomes (behavioral, clinical, or implementation-related), and a plan to reach populations at elevated risk.
18) What types of organizations were eligible to apply?
Eligibility was broad. Eligible applicants included for-profit entities (including small businesses), nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, and government entities at multiple levels (state, county, city/township, and special district).
19) Were tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations were explicitly included as eligible applicants.
20) Were foreign (non-U.S.) organizations eligible?
Yes. The FOA explicitly allowed foreign organizations and foreign institutions to apply. It also allowed non-U.S. components of U.S. organizations and foreign components as defined in NIH policy.
21) Did the FOA encourage participation by specific mission-focused or community-serving institutions?
Yes. It clarified that a wide range of mission-focused and community-serving entities could participate, including faith-based and community-based organizations, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and U.S. territories or possessions.
22) What was the CFDA number associated with this program area?
The CFDA number associated with this program area was 93.279 (Drug Abuse and Addiction Research Programs).
23) Where could applicants find the official NIH posting for PA-12-293?
The announcement directed applicants to the NIH grants posting page at: http://grants.nih.gov/grants/guide/pa-files/PA-12-293.html
24) Who was listed for help with access or linking issues?
The NIH Office of Extramural Research (OER) webmaster contact was provided for access or linking issues: FBOWebmaster@OD.NIH.GOV
25) What does it mean that the opportunity was "investigator-initiated"?
It means the program supported R01 research projects proposed by investigators, centered on the FOA's topic area (drug abuse aspects of HIV/AIDS) rather than restricting proposals to a single predefined study protocol described in the summary.
26) What overarching priority did this FOA reflect at NIDA at the time?
It reflected a priority to integrate substance use research with HIV prevention and care, support work spanning epidemiology through basic biology, and emphasize interventions that could realistically improve outcomes for populations affected by both addiction and HIV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: 2013 PTT Grants
Previous opportunity: Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014 (P50)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 293
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 293) also looked into and applied for these:
| Funding Opportunity |
|---|
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 12 294 Funding Number: PA 12 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 12 295 Funding Number: PA 12 295 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Mechanism for Time Sensitive Drug Abuse Research (R21) Apply for PAR 12 297 Funding Number: PAR 12 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 12 298 Funding Number: PAR 12 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad (ASHA) Program Worldwide Apply for APS ASHA 13 000001 Funding Number: APS ASHA 13 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 13 014 Funding Number: PAR 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Prescription Drug Abuse (R01) Apply for PA 13 015 Funding Number: PA 13 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prescription Drug Abuse (R21) Apply for PA 13 016 Funding Number: PA 13 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 13 001 Funding Number: RFA CA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 13 002 Funding Number: RFA CA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 13 003 Funding Number: RFA CA 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 13 004 Funding Number: RFA CA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Limited Competition Palliative Care Research Co Operative (PCRC) (U24) Apply for RFA NR 13 004 Funding Number: RFA NR 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) Apply for PAR 13 036 Funding Number: PAR 13 036 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA NS 13 007 Funding Number: RFA NS 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS and Cancer Specimen Resource (ACSR) (UM1) Apply for RFA CA 13 005 Funding Number: RFA CA 13 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 13 048 Funding Number: PAR 13 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 293", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.